Clinical Trial Update: Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis patients without the F508del mutation; the trial is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• TRIKAFTA (ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING